X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1835) 1835
Book Review (296) 296
Publication (135) 135
Book Chapter (6) 6
Magazine Article (5) 5
Conference Proceeding (3) 3
Book / eBook (2) 2
Dissertation (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1695) 1695
humans (1358) 1358
male (1015) 1015
female (821) 821
pyrrolidines - therapeutic use (781) 781
pyrrolidines - adverse effects (619) 619
animals (599) 599
middle aged (592) 592
pyrrolidines - pharmacology (512) 512
adult (504) 504
aged (423) 423
pyrrolidines - administration & dosage (373) 373
pharmacology & pharmacy (366) 366
adamantane - analogs & derivatives (317) 317
rats (298) 298
treatment outcome (272) 272
double-blind method (261) 261
diabetes mellitus, type 2 - drug therapy (257) 257
dose-response relationship, drug (217) 217
adamantane - therapeutic use (201) 201
nitriles - therapeutic use (185) 185
abridged index medicus (177) 177
mice (175) 175
vildagliptin (167) 167
pyrrolidines - pharmacokinetics (159) 159
type 2 diabetes (157) 157
adamantane - adverse effects (156) 156
hypoglycemic agents - therapeutic use (156) 156
time factors (155) 155
adolescent (154) 154
endocrinology & metabolism (153) 153
clinical trials as topic (152) 152
nitriles - adverse effects (146) 146
analysis (144) 144
dipeptidyl-peptidase iv inhibitors - therapeutic use (138) 138
drug therapy, combination (135) 135
neurosciences (133) 133
drug therapy (127) 127
pyrrolidines - chemistry (127) 127
administration, oral (126) 126
double-blind (121) 121
pyrrolidines (117) 117
efficacy (115) 115
care and treatment (114) 114
rats, sprague-dawley (114) 114
hypoglycemic agents - adverse effects (107) 107
diabetes mellitus, type 2 - blood (106) 106
diabetes (104) 104
dipeptidyl-peptidase iv inhibitors - adverse effects (97) 97
disease models, animal (96) 96
research (95) 95
medicine & public health (91) 91
aged, 80 and over (90) 90
adamantane - administration & dosage (88) 88
oncology (87) 87
pharmacokinetics (87) 87
blood glucose - metabolism (86) 86
toxicology (84) 84
medicine, general & internal (83) 83
clinical neurology (82) 82
article (81) 81
nitriles - administration & dosage (81) 81
cardiac & cardiovascular systems (80) 80
glucagon-like peptide-1 (80) 80
drugs (78) 78
glycated hemoglobin a - metabolism (76) 76
safety (75) 75
clinical trials (74) 74
glucose (74) 74
young adult (72) 72
beta-cell function (71) 71
internal medicine (71) 71
metformin (70) 70
health aspects (69) 69
rodents (68) 68
migraine disorders - drug therapy (67) 67
therapy (67) 67
dosage and administration (66) 66
blood pressure - drug effects (65) 65
hypoglycemic agents - administration & dosage (64) 64
medicine, research & experimental (64) 64
adamantane - pharmacology (63) 63
blood glucose - drug effects (63) 63
drug-naive patients (63) 63
expression (62) 62
hypoglycemic agents (62) 62
metformin - therapeutic use (62) 62
psychiatry (62) 62
heart rate - drug effects (61) 61
pyrrolidines - metabolism (61) 61
insulin (60) 60
nitriles - pharmacology (60) 60
glycemic control (59) 59
indoles - therapeutic use (59) 59
randomized controlled trials as topic (59) 59
apoptosis (58) 58
atrial fibrillation - drug therapy (58) 58
cancer (58) 58
drug administration schedule (58) 58
pharmacology (58) 58
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1697) 1697
French (65) 65
German (31) 31
Japanese (16) 16
Italian (12) 12
Spanish (11) 11
Russian (7) 7
Czech (3) 3
Dutch (3) 3
Chinese (2) 2
Portuguese (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Polish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Fibrosis | Conductance | Full text | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, ISSN 0363-6119, 03/2008, Volume 294, Issue 3, pp. 842 - 850
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1612 - 1620
This preclinical, phase 2 report shows that VX-445, a CFTR potentiator when administered with tezacaftor and ivacaftor, improved lung function and reduced... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | TEZACAFTOR-IVACAFTOR | CFTR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - administration & dosage | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Chlorides - metabolism | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Pyrazoles - administration & dosage | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Pyridines - pharmacology | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Statistical analysis | Writers | Epithelial cells | Chloride transport | Recovery of function | Patients | Design | Proteins | Genotype & phenotype | Chloride | Collaboration | Fibrosis | Conductance | Full text | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 05/2004, Volume 89, Issue 5, pp. 2078 - 2084
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 2009, Volume 11, Issue 2, pp. 157 - 166
To examine the efficacy and safety of vildagliptin vs. glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus in a 52-week... 
Glimepiride | Vildagliptin | Type 2 diabetes mellitus | Hypoglycaemia | DPP-4 inhibitor | GLUCOSE CONTROL | hypoglycaemia | glimepiride | DRUG-NAIVE PATIENTS | ISLET FUNCTION | PEPTIDASE-IV INHIBITOR | PIOGLITAZONE | THERAPY | vildagliptin | IMPROVES GLYCEMIC CONTROL | TOLERABILITY | ENDOCRINOLOGY & METABOLISM | type 2 diabetes mellitus | DOUBLE-BLIND | CELL-FUNCTION | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Body Weight - drug effects | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Sulfonylurea Compounds - adverse effects | Metformin - adverse effects | Nitriles - administration & dosage | Diabetes Mellitus, Type 2 - blood | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Adamantane - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Type 2 diabetes | Complications and side effects | Care and treatment | Analysis | Glycosylated hemoglobin | Glucose | Dextrose | Diabetes therapy | Index Medicus | Clinical Medicine | Endokrinologi och diabetes | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 01/2015, Volume 172, Issue 2, pp. 532 - 548
Background and PurposeFor patients experiencing inadequate analgesia and intolerable opioid-related side effects on one strong opioid analgesic, pain relief... 
constipation | respiratory depression | buprenorphine | antinociception | rat | fentanyl | oxycodone | intracerebroventricular | morphine‐6‐glucuronide | morphine | M6G | morphine-6-glucuronide (M6G) | DELTA | RATS | RECEPTOR | CEREBROSPINAL-FLUID | ARRIVE GUIDELINES | INTRACEREBROVENTRICULAR MORPHINE | PAIN | PHARMACOLOGY & PHARMACY | BINDING | Fentanyl - adverse effects | Fentanyl - therapeutic use | Pyrrolidines - adverse effects | Male | Diarrhea - chemically induced | Pyrrolidines - therapeutic use | Analgesics, Opioid - adverse effects | Benzeneacetamides - therapeutic use | Pain - drug therapy | Oxycodone - adverse effects | Benzeneacetamides - adverse effects | Morphine Derivatives - adverse effects | Respiratory Insufficiency - physiopathology | Oxycodone - therapeutic use | Enkephalin, D-Penicillamine (2,5)- - therapeutic use | Morphine Derivatives - therapeutic use | Analgesics, Opioid - therapeutic use | Enkephalin, D-Penicillamine (2,5)- - adverse effects | Hot Temperature | Respiratory Insufficiency - chemically induced | Rats, Sprague-Dawley | Constipation - chemically induced | Animals | Buprenorphine - therapeutic use | Castor Oil | Buprenorphine - adverse effects | Diarrhea - drug therapy | Morphine - adverse effects | Morphine - therapeutic use | Morphine | Buprenorphine | Castor oil | Constipation | Narcotics | Rodents | Pain management | Index Medicus | Opioids | Themed Section | New Pathways to Functional Selectivity
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2015, Volume 373, Issue 12, pp. 1106 - 1114
A two-step process, in which circulating levels of amyloid P are reduced and then anti–serum amyloid P antibody is given to activate macrophage clearance... 
MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR MAGNETIC-RESONANCE | QUANTIFICATION | VOLUME | SCINTIGRAPHY | TISSUE | LIVER | SYSTEMIC AMYLOIDOSIS | AL AMYLOIDOSIS | PHARMACOLOGICAL DEPLETION | Liver - pathology | Serum Amyloid P-Component - immunology | Humans | Immunoglobulin G | Middle Aged | Antibodies, Monoclonal - adverse effects | Carboxylic Acids - pharmacokinetics | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Amyloidosis - diagnostic imaging | Dose-Response Relationship, Drug | Carboxylic Acids - adverse effects | Liver - drug effects | Liver - diagnostic imaging | Adult | Carboxylic Acids - administration & dosage | Serum Amyloid P-Component - antagonists & inhibitors | Immunoglobulin Light-chain Amyloidosis | Pyrrolidines - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Amyloidosis - drug therapy | Serum Amyloid P-Component - analysis | Antibodies, Monoclonal - administration & dosage | Radionuclide Imaging | Aged | Infusions, Intravenous | Monoclonal antibodies | Care and treatment | Amyloidosis | Dosage and administration | Immunoglobulins | Kidneys | Mortality | Liver | Inflammation | Scintigraphy | Macrophages | SAP protein | Patients | Lymph nodes | Atrophy | Proteins | Magnetic resonance imaging | Rodents | Giant cells | Drug therapy | Drug dosages | Amyloid P component | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7, pp. 789 - 796
Journal Article
Metabolism, ISSN 0026-0495, 2014, Volume 63, Issue 7, pp. 957 - 967
Abstract Objectives To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia. Material... 
Endocrinology & Metabolism | Glimepiride | Insulin resistance | Vildagliptin | Type 2 diabetes mellitus | Oral fat load | METFORMIN | SITAGLIPTIN | MELLITUS | BETA-CELL FUNCTION | ISLET FUNCTION | PEPTIDASE-IV INHIBITOR | PIOGLITAZONE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Pyrrolidines - adverse effects | Male | Weight Loss - drug effects | Metformin - adverse effects | Pyrrolidines - therapeutic use | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Postprandial Period | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Hypolipidemic Agents - adverse effects | Double-Blind Method | Sulfonylurea Compounds - therapeutic use | Insulin Resistance | Sulfonylurea Compounds - adverse effects | Hyperlipidemias - prevention & control | Diabetes Mellitus, Type 2 - blood | Intention to Treat Analysis | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use | Diabetics | Care and treatment | Diabetes | Comparative analysis | Index Medicus
Journal Article